Overview

Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)

Status:
NOT_YET_RECRUITING

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

Summary

The goal of this Phase I Open-Label study is to demonstrate the safety and feasibility of VentriGel injection in children with Hypoplastic Left Heart Syndrome (HLHS). The main questions it aims to answer are: * Whether VentriGel is safe in treating patients with HLHS * Whether there are any preliminary improvements in measures of cardiac function following Ventrigel injection

Phase:

PHASE1

Details

Lead Sponsor:

Emory University

Collaborators:

University of California, San Diego
Ventrix, Inc.